Study of trastuzumab with chemotherapy and immunotherapy combination for first-line treatment in patients with HER2-positive esophageal squamous cell cancer
Not recruiting
Investigated diseases:Investigated drugs:
Study of belantamab mafodotin combined with pomalidomide, dexamethasone, and daratumumab in patients with relapsed/refractory multiple myeloma who previously had 1-3 treatments and are lenalidomide resistant
Not recruiting
Investigated diseases:Investigated drugs:
Study of HPV vaccine to prevent recurrence of External Genital Warts in previously cured patients: Comparing Human Papillomavirus vaccine versus placebo
Not recruiting
Investigated diseases:Investigated drugs:- Human Papillomavirus Type 11 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
- Human Papillomavirus Type 16 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
- Human Papillomavirus Type 18 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
Study of gemtuzumab ozogamicin and chemotherapy combinations in children with newly diagnosed acute myeloid leukemia, high-risk myelodysplastic syndrome, or myeloid sarcoma
Not recruiting
Investigated diseases:Investigated drugs:
Study of Isatuximab with drug combination for newly diagnosed multiple myeloma patients with severe kidney problems
Not recruiting
Investigated drugs:
Study on the Safety and Effects of Belantamab Mafodotin with Lenalidomide and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Not recruiting
Investigated diseases:Investigated drugs:
Study on the Safety and Effectiveness of PF-07104091 Alone or with Fulvestrant, Letrozole, and Palbociclib for Patients with Advanced Breast, Ovarian, or Lung Cancer
Not recruiting
Investigated diseases:Investigated drugs:
powered by
